Concepedia

Maria Beumont‐Mauviel

MB

Statistics

Publications

26

Citations

2.6K

H-Index

21

Active since

2007

Affiliations

Janssen (Belgium)(Current)

Janssen (United States)

The University of Texas at San Antonio Health Science Center

Janssen (United Kingdom)

University of North Carolina at Chapel Hill

Maria Beumont‐Mauviel is an author at Janssen (Belgium) specializing in antiviral therapy, pharmacy, and viral hepatitis.

Publications per year

2007–2023

26

Publications

26

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial

Ira M. Jacobson, Gregory J. Dore, Graham R. Foster et al. · The Lancet · 2014 · 436 citations

, , +16

Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial

Michael P. Manns, Patrick Marcellin, Fred Poordad et al. · The Lancet · 2014 · 375 citations

, , +16

Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: The randomized PILLAR study

Michael Fried, Gregory J. Dore, Robert Flisiak et al. · Hepatology · 2013 · 271 citations · Full text

, , +17

Simeprevir With Peginterferon and Ribavirin Leads to High Rates of SVR in Patients With HCV Genotype 1 Who Relapsed After Previous Therapy: A Phase 3 Trial

Xavier Forns, Eric Lawitz, Stefan Zeuzem et al. · Gastroenterology · 2014 · 256 citations · Full text

, , +17

Simeprevir Increases Rate of Sustained Virologic Response Among Treatment-Experienced Patients With HCV Genotype-1 Infection: A Phase IIb Trial

Stefan Zeuzem, Thomas Berg, Edward Gane et al. · Gastroenterology · 2013 · 235 citations · Full text

, , +12

1–5 of 26